Stockreport

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

Alector, Inc.  (ALEC) 
Last alector, inc. earnings: 3/24 04:05 pm Check Earnings Report
PDF --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- [Read more]